05 July 2022 : Clinical Research
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania
Xenia Bacinschi1E, Gabriel Cristian Popescu2C, Anca Zgura1C*, Laurentia Gales3F, Anghel Rodica1A, Adriana Mercan4D, Dragos Serban5D, Bogdan Haineala6B, Letitia Toma4C, Laura Iliescu4FDOI: 10.12659/MSM.936706
Med Sci Monit 2022; 28:e936706
Table 3 Biologic abnormalities during direct-acting antiviral agent therapy in patients with and without ribavirin.
| Total group (N=587 patients) | With ribavirin (n=245 patients) | Without ribavirin (n=343 patients) | Chi-square | |
|---|---|---|---|---|
| Anemia | 293 patients (49.91%) | 245 patients (100.0%) | 38 patients (11.07%) | −0.82 |
| Liver cytolysis | 46 patients (7.83%) | 28 patients (11.42%) | 18 patients (5.24%) | −0.41 |
| Cholestasis | 37 patients (6.30%) | 15 patients (6.12%) | 12 patients (3.49%) | −0.23 |